Part 5: Results From TACTIVE-N

We are pleased to present Part 5 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 5 of this series provides peer-to-peer physician perspectives on the results from the TACTIVE-N trial.Topics include:Neoadjuvant vepdegestrant: results of TACTIVE-N trialTolerance in next-generation endocrine therapies: PROTAC estrogen receptor degradersDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly